ClinicalTrials.gg
Active, not recruitingNCT06533540Updated Jul 22, 2025

Safety Study of TPX-121 on Nasolabial Folds

A Phase 1 interventional study of TPX-115(allogeneic fibroblasts) in Nasolabial Fold, Hypoplastic, sponsored by Tego Science, Inc.. Active, not recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by Tego Science, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Study summary

Nasolabial folds augmentation is possible through dermal filler and botulinum toxin, however, safety issues are existed as well as efficacy. Therefore, there is a need for a safer procedure for nasolabial folds correction. This study (Project No. TPX-121) assesses the safety of allogeneic fibroblasts (TPX-115) on nasolabial folds. The safety endpoint is dose-limiting toxicity (DLT). In addition, exploratory endpoints are the improvement of nasolabial folds in Wrinkle Severity Rating Scale (WSRS) at week 4 and 12, change in WSRS and Wrinkle Severity Scale (WSS) at week 4 and 12, and overall appearance improvement rate in Global Aesthetic Improvement Scale (GAIS) at week 4 and 12.

02

Conditions studied

  • Nasolabial Fold, Hypoplastic
03

In context

Lead sponsor

Tego Science, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be 19 years old or older
  2. Have confirmed nasolabial folds severity equal to or more than grade 3 evaluated by WSRS and WSS at face to face evaluation.
  3. Have unsatisfied or very unsatisfied nasolabial folds.
  4. Voluntarily sign the for participation in the study.

Exclusion criteria

Exclusion Criteria:

Current disease and medical history

  1. Inflammatory and infectious skin diseases, unhealed wounds and scars (e.g. Keloids), or benign tumor on nasolabial folds.
  2. Chronic skin diseases (e.g. Psoriasis, Atopic dermatitis).
  3. Genetic diseases that affect fibroblasts or collagen (e.g. Achondroplasia, Osteogenesis imperfecta).
  4. diseases.
  5. Active or C (However, in the case of simple carriers or hepatitis B, except when the antiviral agent was stably taken for 6 months prior to screening).
  6. (HIV) positive.
  7. Coagulopathy.
  8. History of malignant tumors within the last 5 years.
  9. Anaphylaxis or severe combined allergy
  10. Have allergies to bovine proteins or gentamicin.
  11. Acute or chronic infectious diseases.
  12. Severe heart diseases (e.g. Myocardial infarction, Heart failure), severe liver diseases (e.g. Cirrhosis, Liver failure), or severe renal diseases (e.g. Kidney failure).
  13. to amide-based local anesthetics (However, those who agree not to use local anesthetics can register).

    Prohibited drugs and treatments.

  14. Administered systemic within 12 weeks prior to screening or is scheduled to be administered for at least 2 weeks during the study.
  15. Treated cell therapy or stem cell therapy within 1 year prior to screening.
  16. Surgical procedures or surgeries such as fillers or fat grafting on facial part within 1 year prior to screening.
  17. Surgical procedures or surgeries of permanent fillers on facial part prior to screening.
  18. Surgical procedures or surgeries of botulinum toxin injection or face lift surgery on facial part within 6 months prior to screening.
  19. Planned facial cosmetic surgery to improve nasolabial folds during the study.

    Laboratory inspection

  20. Those who fall under the following figures during screening. 1) White blood cell \< 4.5x10\^3/ul and > 11.0x10\^3/ul 2) count \< 100,000/mm\^3 3) \< 9g/dL

    Other

  21. Disagree to take pictures of nasolabial folds
  22. Be pregnant, breastfeeding, planning pregnancy or unwilling to use of contraceptice.
  23. Have participated in other clinical trials and recevied products/devices within 30 days of this study.
  24. Be deemed inadequate for the study by investigators(e.g. A person with severe asymmetry in the lower echocardiogram).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    low dose

    Biological: TPX-115(allogeneic fibroblasts)

  • Experimental
    middle dose

    Biological: TPX-115(allogeneic fibroblasts)

  • Experimental
    high dose

    Biological: TPX-115(allogeneic fibroblasts)

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity

    The number of subjects evaluated grade 3 or higher adverse drug reactions according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: Week 4

Other outcomes

  1. Improvement WSRS grade from baseline

    Improvement Wrinkle Severity Rating Scale (WSRS) grade of nasolabial folds from baseline evaluated by an investigator based on pictures taken at week 4 and 12. The WSRS ranges from 1 (absent) to 5 (Extreme). A negative change from baseline indicates improvement.

    Time frame: Week 4 and Week 12

  2. WSRS grade change from baseline

    Wrinkle Severity Rating Scale (WSRS) grade change from baseline evaluated by an investigator based on pictures taken at week 4 and 12. The WSRS ranges from 1 (absent) to 5 (Extreme). A negative change from baseline indicates improvement.

    Time frame: Week 4 and Week 12

  3. WSS grade change from baseline

    Wrinkle Severity Scale (WSS) grade change from baseline evaluated by an investigator based on pictures taken at week 4 and 12. The WSS ranges from 0 (absent) to 5 (Extreme). A negative change from baseline indicates improvement.

    Time frame: Week 4 and Week 12

  4. Overall appearance improvement percentage(%) using GAIS

    Overall appearance improvement percentage(%) rated by subjects using Global Aesthetic Improvement Scale (GAIS) at week 4 and 12. In the case of overall appearance improvement rate using GAIS being +3 point (Very much improved), +2 (Much improved), or +1 (Improved)

    Time frame: Week 4 and Week 12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Mar 2026, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Aug 1, 2024
StartActual
Dec 11, 2024
Primary completionEst.
Mar 2026
CompletionEst.
Dec 2026
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06533540
Lead sponsor
Tego Science, Inc.
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Dec 11, 2024
Primary completion
Mar 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 22, 2025

Study contacts

Hoyun Chung, M.D.
principal investigator · Kyungpook National University, School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TPX-115

Start the discussion